Company Profile

Akouos Inc. precision genetic medicine company focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals. The Company is focused on developing precision therapies for forms of sensorineural hearing loss. The Company's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The Company is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.

Employees

103

Sector

Biotechnology & Medical Research

More about the company

23/01/24	Akouos, Inc. Announces Positive Initial Clinical Results from the Phase 1/2 AK-OTOF-101 Study	CI
02/12/22	Akouos, Inc. Announces Executive and Board Changes	CI
01/12/22	Lilly Wraps Up Acquisition of Akouos	MT
01/12/22	Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Composite Index	CI
01/12/22	Eli Lilly and Company completed the acquisition of Akouos, Inc. from a group of shareholders.	CI
30/11/22	Eli Lilly's Buyout Offer Accepted by 81% Akouos Shareholders at Closing	MT
30/11/22	Akouos, Inc.(NasdaqGS:AKUS) dropped from S&P TMI Index	CI
29/11/22	Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Biotechnology Index	CI
14/11/22	Akouos Q3 Loss Narrows	MT
14/11/22	Akouos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
19/10/22	Piper Sandler Downgrades Akouos to Neutral From Overweight, Adjusts Price Target to $13 From $18	MT
19/10/22	William Blair Downgrades Akouos to Market Perform From Outperform	MT
18/10/22	Health Care Up Amid Earnings, Deals -- Health Care Roundup	DJ

19/10/22	Piper Sandler Downgrades Akouos to Neutral From Overweight, Adjusts Price Target to $13 From $18	MT
19/10/22	William Blair Downgrades Akouos to Market Perform From Outperform	MT
18/10/22	HC Wainwright Downgrades Akouos to Neutral from Buy	MT
29/09/22	William Blair Starts Akouos at Outperform	MT
18/05/22	Piper Sandler Adjusts Akouos' Price Target to $18 From $40, Reiterates Overweight Rating	MT

02/12/22	AKOUOS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
30/11/22	Lilly and Akouos Announce Expiration of Akouos Tender Offer	PR
14/11/22	AKOUOS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
14/11/22	AKOUOS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
14/11/22	Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights	AQ

01/12/22	Eli Lilly : a finalisé l'acquisition d'Akouos
30/11/22	Eli Lilly : vers l'acquisition de 81.1% des actions d'Akouos
19/10/22	Wall Street sluit hoger
18/10/22	Wall Street houdt winst vast
18/10/22	MÄRKTE USA/Börsen setzen Erholung fort

Manager	Title	Age	Since
Emmanuel J. Simons CEO	Chief Executive Officer	43	01/01/2016
Jean Phillips CTO	Chief Tech/Sci/R&D Officer	-	-
Aaron Tward CTO	Chief Tech/Sci/R&D Officer	-	10/03/2022

AKOUOS Stock

Stocks

AKUS

US00973J1016

Biotechnology & Medical Research

Latest news: AKOUOS

Analysts' recommendations: AKOUOS

Press Releases: AKOUOS

News in other languages: AKOUOS

Quotes and Performance

Managers and Directors: AKOUOS

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/12/22	Sona Saira Ramasastry	Issuer sale	Director	16,000	0.0433%
01/12/22	Vicki Sato	Issuer sale	Director	55,030	0.1489%
01/12/22	Sachiyo Minegishi	Issuer sale	Chief Financial Officer	150,000	0.4060%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AKOUOS	+1.06%	+0.91%	-	-	491M
WUXI APPTEC CO., LTD.	+5.04%	+3.27%	+50.62%	+105.43%	66.93B
ARGENX SE	+1.64%	-0.18%	+34.67%	+76.81%	61.97B
INSMED INCORPORATED	-3.18%	-0.78%	-14.14%	+369.82%	28.26B
WUXI BIOLOGICS (CAYMAN) INC.	+4.55%	-0.08%	+34.70%	+17.28%	24.59B
BIONTECH SE	+2.20%	-4.72%	+2.19%	-13.14%	24.3B
GENMAB A/S	+1.15%	-2.26%	+17.56%	-16.53%	19.41B
PHARMAESSENTIA CORPORATION	-7.03%	-9.16%	+161.91%	+303.00%	16.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.44%	-1.68%	-5.00%	+541.17%	14.18B
SUMMIT THERAPEUTICS INC.	+4.96%	+4.63%	-2.75%	+864.40%	14B
Average	+1.38%	-3.94%	+31.09%	+249.80%	30.05B
Weighted average by Cap.	+1.98%	-2.84%	+33.25%	+173.47%